LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Inicio・Lista de Acciones・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

210.23 2.33

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

208.84

Máximo

210.59

Métricas clave
By Trading Economics
Ingresos	-22M -61M
Ventas	56M 214M
Margen de beneficio	-28.549
Empleados	1,017
EBITDA	-56M -53M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+25.68% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	902M 13B
Apertura anterior	207.9
Cierre anterior	210.23

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

157.66 / 167.29 Soporte y Resistencia

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 nov 2025, 16:49 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov 2025, 15:32 UTC

Adquisiciones, fusiones, absorciones

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov 2025, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 nov 2025, 16:05 UTC

Charlas de Mercado

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov 2025, 16:04 UTC

Charlas de Mercado

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov 2025, 15:54 UTC

Adquisiciones, fusiones, absorciones

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov 2025, 15:44 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov 2025, 15:43 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov 2025, 15:42 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov 2025, 15:41 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov 2025, 15:11 UTC

Charlas de Mercado

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov 2025, 14:26 UTC

Charlas de Mercado

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov 2025, 14:11 UTC

Charlas de Mercado

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov 2025, 14:11 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 nov 2025, 13:35 UTC

Charlas de Mercado

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov 2025, 13:33 UTC

Charlas de Mercado

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov 2025, 13:22 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 nov 2025, 13:22 UTC

Charlas de Mercado

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov 2025, 13:17 UTC

Charlas de Mercado

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov 2025, 11:13 UTC

Charlas de Mercado

European Gas Prices Come Under Pressure -- Market Talk

27 nov 2025, 11:07 UTC

Ganancias

Genting: Positive About Prospects Over Longer Term

27 nov 2025, 11:06 UTC

Ganancias

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov 2025, 11:04 UTC

Ganancias

Genting: International Travel Demand Expected to Remain Resilient

27 nov 2025, 11:04 UTC

Ganancias

Genting: Global Growth Expected to Remain Subdued

27 nov 2025, 11:04 UTC

Ganancias

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov 2025, 10:59 UTC

Ganancias

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov 2025, 10:58 UTC

Ganancias

Genting Bhd 3Q Rev Rose 14% on Year

27 nov 2025, 10:56 UTC

Ganancias

Genting Bhd 3Q Net MYR30.3M

27 nov 2025, 10:56 UTC

Ganancias

Genting Bhd 3Q EPS MYR0.0079

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

25.68% repunte

Estimación a 12 meses

Media 259.71 USD 25.68%

Máximo 325 USD

Mínimo 220 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.